-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing, October 28, 2021/PRNewswire/ - Recently, the National Medical Products Administration (NMPA) has approved Novo Nordisk's research and development and production of Novo Nordisk® (Degulin and Liraglutide Injection) in In China’s marketing application, this product is suitable for adult type 2 diabetes patients with poor blood sugar control.
It is combined with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control [1]
.
Novoyi® is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, which is composed of insulin deglubber and liraglutide [2], a breakthrough integration of deglu The two-component advantages of insulin and liraglutide, complementary mechanisms, multi-targeted action on multiple pathophysiological mechanisms of type 2 diabetes[3],[4],[5], once a day, powerful control of blood sugar throughout the day , The glycated hemoglobin (HbA1c) compliance rate is as high as 89.
9%, which reduces the risk of hypoglycemia and has clear weight gains[6],[7],[8],[9],[10], which will bring easy control for patients Blood glucose management helps Chinese patients with type 2 diabetes reach high-quality blood glucose standards
.
At present, deglu insulin and liraglutide injection have been written into the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)" [11]
The total number of diabetes patients in China is 129.
8 million [12], and only about 15.
8% of patients have blood glucose control standards [13]
.
Among them, type 2 diabetes accounts for the majority
Professor Wang Weiqing, director of the Department of Endocrinology and Metabolism, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, affirmed the performance of this innovative drug in clinical trials: “China's Phase 3 randomized study DUAL Ⅰ confirmed that oral hypoglycemic drugs in China with poor blood glucose control 2 In patients with type 2 diabetes, insulin degludec and liraglutide injection can effectively reduce HbA1c, while the risk of hypoglycemia is low, patients gain less weight, and the daily insulin injection dose is less, which is consistent with the results of the global phase 3 study
.
"
"Insulin deglulam and liraglutide injection combine the dual advantages of the basal insulin deglulam and GLP-1RA liraglutide.
The two complement each other and target the underlying pathophysiological mechanism of type 2 diabetes.
The HbA1c compliance rate has reached a breakthrough of 89.
9%, which is an innovative drug worth looking forward to,” said Professor Mu Yiming, director of the Endocrinology Department of the PLA General Hospital
.
At the same time, he also recognized the benefits of insulin deglulam and liraglutide injection for patients who have started insulin: “Patients still have many unmet clinical needs after the initiation of insulin therapy, such as HbA1c failure, Multiple factors such as the risk of hypoglycemia, weight gain, and complexity in the treatment plan have led to poor medication compliance, which has become a major obstacle to blood glucose control in patients with type 2 diabetes
Zhang Kezhou, Corporate Vice President of the Pharmaceutical and Quality Department of Novo Nordisk Greater China, pointed out: "The approval of Novo Nordisk® can be said to be another new achievement of Novo Nordisk's dream of developing new drugs particularly suitable for Chinese patients
.
China 2 The beta cells of type 2 diabetes patients are more prone to exhaustion and high blood sugar after a meal.
Zhou Xiaping, Senior Vice President and President of Greater China of Novo Nordisk, said: "Thanks to the National Medical Products Administration and related departments for their strong support and guidance in accelerating the introduction of innovative drugs into China, and thanks to researchers and clinical trial subjects for their contributions! 2021 is the 100th anniversary of the discovery of insulin by humans.
As a global leader in the field of diabetes treatment, Novo Nordisk is committed to continuous innovation to bring safer and more effective products to patients
.
Combining insulin and GLP-1RA therapies into one Among these drugs, Novo Nordisk has made another breakthrough innovation in the field of diabetes treatment
About Novo
Nuovoyi® is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, which is composed of insulin deglubber and liraglutide [2]
.
Novoyi® uses recombinant DNA technology and is made from Saccharomyces cerevisiae.
About Novo Nordisk
Founded in 1923, Novo Nordisk is a leading global biopharmaceutical company headquartered in Denmark
.
Our goal is to promote change to overcome diabetes, obesity, rare blood diseases, endocrine disorders and other serious chronic diseases
[2] Gough S, et al.
[3] Baggio L, Drucker DJ.
Gastroenterology.
2007 May;132(6):2131-57.
[4] Niswender KD.
Postgrad Med.
2011 Jul;123(4):27-37.
[5] Veelen A, et al.
Mol Metab.
2021 Apr;46:101158.
[6] Harris SB, et al.
Diabetes Obes Metab.
2017 Jun;19(6):858-865.
[7] Buse JB, et al.
Diabetes Care.
2014 Nov;37(11):2926-33.
[8] Lingvay I, et al.
JAMA.
2016 Mar 1;315(9):898-907.
[9] Philis-Tsimikas A, et al.
Diabetes Obes Metab.
2019 Jun;21(6):1399-1408.
[10] Billings LK, et al.
Diabetes Care.
2018 May;41(5):1009-1016.
[11] Diabetes Branch of Chinese Medical Association.
Chinese Journal of Diabetes.
2021; 13(4):315-409.
[12] Yongze Li, et al.
BMJ.
2020 Apr 28;369:m997.
[13] Wang L, et al.
JAMA.
2017 Jun 27;317(24):2515-2523.
[14] Cernea S, Raz I.
Diabetes Care.
2011 May;34 Suppl 2(Suppl 2):S264-71.
[15] Østergaard L, et al.
Expert Rev Clin Pharmacol.
2017 Jun;10(6):621-632.
[16] Miller E, et al.
Diabetes Obes Metab.
2019 Dec;21(12):2643-2650.
Source: Novo Nordisk
